

In response to the Office Action of July 24, 2003, please amend the application as follows:

IN THE CLAIMS

29. (Currently Amended) An inclusion A complex of paroxetine, as a free base or as a salt, with a cyclodextrin or with a cyclodextrin derivative.

30. (Currently Amended) The inclusion complex as claimed in claim 29, wherein it is in the form of a flowing powder, it has a greater stability in comparison with the non-complexed paroxetine, organic solvents are absent, it has a higher solubility in water with respect to the non-complexed paroxetine and a DSC profile different from that of the corresponding non-complexed paroxetine or paroxetine salt.

31. (Currently Amended) The inclusion complex as claimed in claim 30, wherein ethanol is absent.

32. (Currently Amended) The inclusion complex as claimed in claim 29, having a water content of between 1 and 20% by weight.

33. (Currently Amended) The inclusion complex as claimed in claim 32, wherein the water content is between 2 and 15% by weight.

34. (Currently Amended) The inclusion complex as claimed in claim 29, wherein the cyclodextrin is selected from the group consisting of  $\alpha$ ,  $\beta$  and  $\gamma$ -cyclodextrin.

35. (Currently Amended) The inclusion complex as claimed in claim 34, wherein the cyclodextrin is a  $\beta$ -cyclodextrin.

36. (Currently Amended) The inclusion complex as claimed in claim 29, wherein the cyclodextrin derivative is selected from the group consisting of heptakis (2,6-

di-O-methyl)- $\beta$ -cyclodextrin, heptakis (2,3,6-tri-O-methyl)- $\beta$ -cyclodextrin, monosuccinyl-heptakis(2,6-di-O-methyl)- $\beta$ -cyclodextrin, 2-hydroxypropyl- $\beta$ -cyclodextrin, sulphated cyclodextrin and cyclodextrin containing aminoalkyl groups.

5        37. (Currently Amended) The inclusion complex as claimed in claim 36, wherein the cyclodextrin derivative is the 2-hydroxypropyl- $\beta$ -cyclodextrin.

38. (Currently Amended) The inclusion complex as claimed in claim 29, wherein the salt of paroxetine is a salt with an organic or inorganic acid.

10       39. (Currently Amended) The inclusion complex as claimed in claim 38, wherein said organic or inorganic acid is selected from the group consisting of acetic acid, maleic acid, hydrochloric acid and methanesulfonic acid.

40. (Currently Amended) The inclusion complex as claimed in claim 39, wherein said acid is hydrochloric acid.

15       41. (Currently Amended) The inclusion complex as claimed in claim 29, wherein the molar ratio between paroxetine and said cyclodextrin or cyclodextrin derivative ranges from 1:0.25 to 1:20.

42. (Currently Amended) The inclusion complex as claimed in claim 41, wherein the molar ratio between paroxetine and said cyclodextrin or cyclodextrin derivative ranges from 1:0.5 to 1:2.

20       43. (Previously Added) A pharmaceutical composition containing as an active substance a pharmaceutically effective dose of an inclusion complex as defined in claim 29, in mixture with pharmaceutically acceptable diluents or excipients.

44. (Previously Added) The pharmaceutical composition as claimed in claim 43 in solid or liquid form, for oral and for parenteral administration.